Sarepta Therapeutics Q4 Loss Increases, but beats estimates

(RTTNews) - Sarepta Therapeutics (SRPT) revealed Loss for fourth quarter that decreased from the same period last year but missed the Street estimates.

The company's bottom line came in at -$121.98 million, or -$1.42 per share. This compares with -$189.32 million, or -$2.40 per share, in last year's fourth quarter.

Excluding items, Sarepta Therapeutics reported adjusted earnings of -$66.01 million or -$0.77 per share for the period.

Analysts on average had expected the company to earn -$1.13 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 38.8% to $201.46 million from $145.14 million last year.

Sarepta Therapeutics earnings at a glance (GAAP) :

-Earnings (Q4): -$121.98 Mln. vs. -$189.32 Mln. last year. -EPS (Q4): -$1.42 vs. -$2.40 last year. -Analyst Estimates: -$1.13 -Revenue (Q4): $201.46 Mln vs. $145.14 Mln last year.